



OPEN ACCESS

EDITED AND REVIEWED BY
Cleber Machado-Souza,
Pelé Pequeno Príncipe Research Institute,
Brazil

*CORRESPONDENCE
Lu-jun Zhao
✉ zhaolujun@tjmuch.com
Yan Wang
✉ mgwy1974@163.com

†These authors have contributed equally to
this work

RECEIVED 19 September 2025
ACCEPTED 03 October 2025
PUBLISHED 08 October 2025

CITATION
Zhang J, Guo J-x, Li P, Jin X-y, Wang Y and
Zhao L-j (2025) Correction: Real-world
outcomes of immune checkpoint inhibitors
as second-line therapy for extensive-stage
small-cell lung cancer: a multicenter
retrospective analysis.
Front. Immunol. 16:1708889.
doi: 10.3389/fimmu.2025.1708889

COPYRIGHT
© 2025 Zhang, Guo, Li, Jin, Wang and Zhao.
This is an open-access article distributed under
the terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or reproduction
is permitted which does not comply with
these terms.

Correction: Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis

Jiao Zhang^{1,2†}, Jia-xing Guo^{3†}, Ping Li⁴, Xiao-ye Jin⁵,
Yan Wang^{1*} and Lu-jun Zhao^{2*}

¹The Third Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China, ²Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China, ³Department of Radiation Oncology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, China, ⁴Department of Pharmacy, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China, ⁵College of Clinical Medical, Ningxia Medical University, Yinchuan, Ningxia, China

KEYWORDS

extensive-stage small cell lung cancer, immune checkpoint inhibitors, second-line therapy, survival, prognosis

A Correction on

Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis

By Zhang J, Guo J-x, Li P, Jin X-y, Wang Y and Zhao L-j (2025). *Front. Immunol.* 16:1658017. doi: 10.3389/fimmu.2025.1658017

In the **Abstract**, In the **Results** section of the **Abstract**: Line 4: The values “4.14 vs. 2.84” are incorrect. Line 5: The values “4.21 vs. 2.87” are incorrect. This has been corrected to read:

Line 4: The original data has been changed to “4.13 vs. 2.70”. Line 5: The original data has been changed to “4.14 vs. 2.84”.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.